Microsoft Signs Deal for Major Manhattan Offices on Fifth Avenue

Microsoft Signs Deal for Major Manhattan Offices on Fifth Avenue

Microsoft corp:

 is the latest technology tenant to expand in Manhattan, even as most employees continue to work remotely. 

The company signed a lease for 150,000 square feet (14,000 square meters) of space at 122 Fifth Ave. in the Flatiron district, according to a person familiar with the matter. 

The 300,000-square-foot building, owned by Bromley Cos., is undergoing a major renovation project and includes retail space. 

The move comes amid a flurry of deals by tech firms seeking to expand in New York despite delays in return-to-office plans. In September, Google

agreed to pay $2.1 billion for a west side project that it already leases. Facebook and Inc. are among companies looking for more space, Bloomberg reported earlier this year. 

Newmark Group Inc. represented the landlord and Jones Lang LaSalle Inc. represented Microsoft.

A spokesman for Newmark declined to comment. Representatives for JLL, Bromley and Microsoft didn’t immediately respond to requests for comment. 

Apple Inc. unveiled a new iPhone 13 at a wide-ranging product event Tuesday, looking to entice consumers with improvements to the camera and processor in lieu of major design changes. It also showed off a new Apple Watch. Bloomberg's Tom Giles reports. (Source: Bloomberg)



Age of Empires Is Part of Microsoft’s Bid to Conquer the PC Game World

The U.S. Food and Drug Administration issued an emergency use authorization for the vaccine on October 29. That authorization had passed its first hurdle a few days ago when an FDA advisory panel gave their thumbs-up to make Pfizer’s and its German partner BioNTech’s vaccine available to 5- to 11-year-olds.  

Advisers to the U.S. Centers for Disease Control and Prevention will meet November 2 to discuss authorization and develop recommendations for the vaccine’s use in this age group. The shots could be available as early as next week.

The decision to endorse emergency use authorization of the vaccine followed an extensive discussion among experts on the FDA panel, who were tasked with determining if the vaccine’s benefits outweigh the risks. 


97 Blog posts